Hilary Daniel, BS; for the Health and Public Policy Committee of the American College of Physicians *
Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations.
Financial Support: Financial support for the development of this guideline comes exclusively from the ACP operating budget.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-2768.
Requests for Single Reprints: Hilary Daniel, BS, American College of Physicians, 25 Massachusetts Avenue NW, Suite 700, Washington, DC 20001; e-mail, email@example.com.
Conception and design: H. Daniel, D.M. DeLong, R.H. Lohr, D.V. Moyer, K.E. Olive, F.Z. Syed.
Analysis and interpretation of the data: J.F. Bush, H. Daniel, S.U. Rehman.
Drafting of the article: H. Daniel, D.V. Moyer, F.Z. Syed.
Critical revision for important intellectual content: M. Beachy, M. Biermann, H. Daniel, D.M. DeLong, G.C. Kane, R.H. Lohr, D.V. Moyer, S.U. Rehman, F.Z. Syed.
Final approval of the article: M. Beachy, M. Biermann, S.S. Bornstein, J.F. Bush, H. Daniel, D.M. DeLong, G.A. Hood, C.A. Horwitch, G.C. Kane, R.H. Lohr, D.V. Moyer, K.E. Olive, S.U. Rehman, F.Z. Syed.
Collection and assembly of data: H. Daniel, F.Z. Syed.
This American College of Physicians position paper, initiated and written by its Health and Public Policy Committee and approved by the Board of Regents on 16 February 2016, reports policy recommendations from the American College of Physicians to address the escalating costs of prescription drugs in the United States. Prescription drugs play an important part in treating and preventing disease. However, the United States often pays more for some prescription drugs than other developed countries, and the high price and increasing costs associated with prescription medication is a major concern for patients, physicians, and payers. Pharmaceutical companies have considerable flexibility in how they price drugs, and the costs that payers and patients see are dependent on how payers are able to negotiate discounts or rebates. Beyond setting list prices are issues of regulatory approval, patents and intellectual property, assessment of value and cost-effectiveness, and health plan drug benefits. These issues are linked, and comprehensive efforts will be needed to affect how drugs are priced in the United States.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Daniel H, for the Health and Public Policy Committee of the American College of Physicians. Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of Physicians. Ann Intern Med. ;165:50–52. doi: 10.7326/M15-2768
Download citation file:
Published: Ann Intern Med. 2016;165(1):50-52.
Published at www.annals.org on 29 March 2016
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use